Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know

This story originally appeared on Zacks

Edwards Lifesciences (EW) closed the last trading day at $118.26, up -1.83% from the previous trading session. This change delayed the daily gains for the S&P 500 by 0.08%. Meanwhile, the Dow Jones lost 0.56%, and the tech-heavy Nasdaq lost 0.42%.

– Zacks

As the day started, shares of the medical device maker were up 0.74% in the last month. At the same time, the medical sector lost 4.1%, while the S&P 500 rose 0.22%.

Investors are hoping for some strength from Edwards Lifesciences as it nears its next earnings release. In this report, analysts expect Edwards Lifesciences to report earnings of $0.54 per share. This represents an annual growth of 8%. Our latest consensus estimate calls for quarterly revenue of $1.35 billion, an increase of 12.96% over the same period last year.

It’s also important to note recent changes in analyst estimates for Edwards Lifesciences. These reviews usually reflect the latest short-term business trends, which can change frequently. With this in mind, we can take the positive rating reviews as a sign of optimism about the company’s business outlook.

Our research shows that these discretionary changes are directly correlated with near-term stock prices. We developed Zacks Rank to take advantage of this phenomenon. Our system takes these discretionary changes into account and provides a clear and actionable rating model.

The Zacks Rank system ranges from #1 (strong buy) to #5 (strong sell). The company has a proven track record of success, subject to external scrutiny, with the No. 1 stock having generated an average annual return of over 25% since 1988. In the past 30 days, our aligned EPS forecast is up 0.14%. Edwards Lifesciences has a Zacks rank of 3rd (Hold) at the moment.

When looking at valuation, Edwards Lifesciences currently has a forward P/E ratio of 47.53. This is a premium over the industry’s average forward P/E of 44.02.

Meanwhile, the electronic warfare fair value price ratio is currently 3.39. This metric is used similarly to the popular P/E ratio, but the PEG ratio also takes into account the expected earnings growth rate for a stock. The Medical – The instruments had an average price to USD ratio of 2.52 at yesterday’s closing price.

The medical instrument industry is part of the medical sector. This group has a Zacks Industry Rating of 168, placing it in the bottom 35% of all 250+ industries.

The Zacks Industry Ranking measures the strength of our individual industry groups by measuring the average Zacks rating of the individual stocks within the groups. Our research shows that industries ranked 50% outperform the bottom half by a factor of 2 to 1.

You can find more information about all of these metrics and more at Zacks.com.

Infrastructure stock boom to sweep America

A massive push to rebuild America’s crumbling infrastructure will soon begin. It is certain, urgent and inevitable. Trillions will be spent. fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a special report to help you do just that, and it’s free today. Discover 5 private companies looking to get the most from construction and repairs to roads, bridges and buildings, as well as moving goods and transforming energy on an almost unimaginable scale.

Download for free: How to capitalize on trillions of infrastructure spending >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 of the best stocks for the next 30 days. Click for this free report

Edwards Lifesciences (EW): Free Inventory Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

.

Leave a Comment